Metabolic disease Differential drug response in lean and obese patients explained
|
One thing that predisposes individuals who are obese to type 2 diabetes is the persistent, low-level inflammation that results, in part, from dysregulation of the function of white fat tissue in the abdominal cavity between the internal organs (visceral white fat tissue). New insight into the signaling pathways that contribute to visceral white fat tissue dysregulation has now been provided by researchers who determined that the PPAR-gamma signaling pathway operates differently in the visceral white fat tissue of lean and obese mice and humans.
User comments, Ratings and Reviews
Read more!
[Bookmark & read later
/ Comment this story ]
/ realated stories]
Article Taged as : metabolic, disease, differential, drug, response, lean, obese, patients, explained, http, feeds.sciencedaily.com, sciencedaily, f3fyq3xqhq0, 100401220646.htm, http, www.sciencedaily.com, newsfeed.xml, sciencedaily, magazine, metabolic, disease, differential, drug, response, lean, obese, patients, explained,
|
Article Statistics
Article Viewed 1141 times.
Positive attitude 1 votes [0%]
Negetive attitude 1 votes [0%]
News Article Source & Groups
sciencedaily magazine
your link to the latest research news. daily headlines about discoveries in the physical and life sciences, health and medicine, the environment, and technology, from the world's leading universities and research centers.
The Submitted XML Type text/xml; charset=UTF-8 and gathered so far 334956 bytes of news and keep on growing.
Submit Server name is GSE and Code Page 65001 (Not Defined/Un Known)
: : Metabolic disease Differential drug response in lean and obese patients explained
Date Listed : Sunday, April 04, 2010
Source : ,
|
Related Stories
- Stephen Tsang, Columbia University - Keynote Speaker at Ocular Disease Conference
Stephen Tsang, Associate Director, Edward S. Harkness Eye Institute, Columbia University/New York Presbyterian Hospital will give a Keynote Presentation on Transplantation of Reprogrammed Embryonic Stem Cells Improves Visual Function in ...- Redpages Getting Good Response for Customized email Notification Service
Aklan, Philippines, 18 March 2010 : Redpages, the leading online directory in Philippines is getting an encouraging response for the free of cost customized email notification service it has ...- Huntington's Disease - Drug Pipeline Analysis and Market Forecasts to 2016
The global Huntington’s disease (HD) market was worth $243m in 2009. The market is expected to grow by 17.4% during the next seven years to reach $748m by 2016. Earlier, ...- Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
The coronary artery disease (CAD) market is a highly competitive market and is expected to become more competitive until 2016. Three major patent expiries are expected during the forecast period, ...- Â Infectious Diseases Drugs Markets
According to the World Health Organization (WHO), six infectious diseases--pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS--account for half of all premature deaths worldwide, killing mostly children and young adults. ...- Barbara Wirostko, Pfizer â€" to present at the 2nd Annual Ocular Disease Conference
Barbara Wirostko, Senior Medical Director, Team Lead Ophthalmology, Pfizer will present on Endothelin: A Potential Novel Mechanism for Future Drug Development in Ophthalmology at GTCbio’s 2nd Annual Ocular Disease ...- Paget’s Disease - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData’s analysis reveals that the Paget’s disease market was worth $159.2m in 2009. It is forecast to exhibit a negative compound annual growth rate (CAGR) of 8.9% for the next ...- Lyme Disease - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData estimated that the Lyme disease market was worth $2.2m in 2009. The major reason for the limited market revenues is that there is no approved drug for Lyme disease ...- Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData’s analysis suggests that the global chronic kidney disease (CKD) market was worth $13.3 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of ...- Atherosclerosis Or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
The CAD market is currently very competitive and is expected to get more competitive in the future. The market is expected to witness a decline between 2011 and 2013 due ...
|
|
|
